设计,合成和抗癌评价新型库马林/提亚类同源作为具有分子动态的潜在CDK2抑制剂

Samir Bondock1, Nada Alabbad1, Aisha Hossan1

  • 1Chemistry Department, Faculty of Science, King Khalid University 9004 Abha Saudi Arabia bondock@kku.edu.sa bondock@mans.edu.eg.

RSC advances
|June 14, 2024
PubMed
概括

新型库马林-提亚化合物通过抑制循环素依赖激酶2 (CDK2) 来显示出作为抗癌剂的前景. 衍生6c对HepG2和HCT116癌细胞系表现出强大的抗癌活性.

相关概念视频

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K